The company was founded in December 2011 by a team of life-sciences experts previously involved in the development and approval of sugammadex (Bridion™), the first modified cyclodextrin (CD) marketed as a drug product.
What we offer
Unique expertise in development of cyclodextrin-based therapeutics
Track-record of successful submissions and approvals in EU, US and Japan
SME partner in collaborative (pre-competitive) projects
Partnering and licensing opportunities